Education
About Us
Working with TipRanks
Follow Us
Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
RESEARCH TOOLSreports
DRTS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.75 - $4.39
Previous CloseN/A
Volume116.73K
Average Volume (3M)92.02K
Market Cap
$181.80M
Enterprise Value$110.76M
Total Cash (Recent Filing)$457.75K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.81
Next Earnings
May 21, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding69,924,160
10 Day Avg. Volume92,438
30 Day Avg. Volume92,023
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-103.13
Enterprise Value/Ebitda-3.21
Forecast
1Y Price Target
$9.00Price Target Upside242.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Alpha Tau Medical Ltd News
PremiumCompany Announcements
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences
PremiumCompany Announcements
Alpha Tau Achieves MDSAP Certification, Boosting Global Expansion Efforts
PremiumCompany Announcements
Alpha Tau Gains FDA Approval to Expand Pancreatic Cancer Trial
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe proprietary Alpha DaRT technology for the localized treatment of solid tumors stands apart, demonstrating durable efficacy and favorable safety.
Regulatory ApprovalAlpha DaRT has been accepted into the Total Product Life Cycle Advisory Program (TAP) Pilot of the U.S. FDA to accelerate market access for patients with recurrent glioblastoma multiforme.
Bears Say
Market CompetitionOptions to invest in publicly traded radiopharma names have grown increasingly scarce, making DRTS an overlooked exception.
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.66% Other Institutional Investors
99.29% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $1.75 and its highest was $4.39 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $181.80M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is May 21, 2025 which is in 70 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Currently, no data Available
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.13.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 69,924,160 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
---
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (242.21% Upside)
$9.00 (242.21% Upside)
Hedge Fund Trend
Decreased
By 60.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ―
Last 30 Days ―
Last 30 Days ―
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.33%
12-Months-Change
Fundamentals
Return on Equity
-37.22%
Trailing 12-Months
Asset Growth
-15.00%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau is an Israel-based medical device company focusing on the research, development, and potential commercialization of the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumors.
---
DRTS Stock 12 Month Forecast
Average Price Target
$9.00
▲(242.21% Upside)
Technical Analysis
Best Analysts Covering DRTS
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-6.80%
reiterated a buy rating 4 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -6.80% per trade.
---